<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40626521</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Nodal Downstaging in Patients With Rectal Cancer: Survival Is Promising if YpN0 Is Achieved.</ArticleTitle><Pagination><StartPage>1162</StartPage><EndPage>1171</EndPage><MedlinePgn>1162-1171</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003846</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Locally advanced rectal cancer is a critical health concern, with neoadjuvant therapy emerging as a pivotal strategy to enhance survival rates.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to evaluate the prognostic value of achieving ypN0 status after neoadjuvant therapy in patients with locally advanced rectal cancer, comparing survival outcomes among natural N0, downstaged N0, and ypN + groups.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We conducted a post hoc analysis of the FOWARC trial (neoadjuvant FOLFOX6 chemotherapy with or without radiation) using Kaplan-Meier survival analysis and Cox regression models to assess overall survival, disease-free survival, and locoregional recurrence-free survival.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">The multicenter, randomized phase III FOWARC trial was conducted across 15 hospitals in China, adhering to the highest ethical standards.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Our cohort included 449 patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiotherapy followed by total mesorectal excision.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Neoadjuvant chemoradiotherapy followed by total mesorectal excision.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The primary end point was 5-year overall survival, with secondary end points being 3-year disease-free survival and 3-year locoregional recurrence-free survival.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 5-year overall survival rates for natural N0 and downstaged N0 groups were 88% and 89%, respectively, significantly higher than the 73% observed in the ypN + group ( p = 0.0034). The complete pathological response rate was markedly lower in the ypN + group. Multivariable analysis revealed that the ypN stage is an independent prognostic factor for overall survival.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The study's retrospective design may introduce potential biases in patient selection and preoperative staging.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Achieving ypN0 status via neoadjuvant chemoradiotherapy significantly improves survival in patients with locally advanced rectal cancer, regardless of ypT or cN status. This status not only serves as an independent prognostic factor but may also help guide hypothesis-driven, individualized postoperative treatment strategies. See Video Abstract .</AbstractText><AbstractText Label="CLINICAL TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT01211210.</AbstractText><AbstractText Label="REDUCCIN DEL ESTADIO NODAL EN PACIENTES CON CNCER RECTAL LA SUPERVIVENCIA ES PROMETEDORA SI SE ALCANZA YPN" NlmCategory="UNASSIGNED">ANTECEDENTES:El c&#xe1;ncer rectal localmente avanzado es un problema de salud cr&#xed;tico, y la terapia neoadyuvante se est&#xe1; imponiendo como una estrategia fundamental para mejorar las tasas de supervivencia.OBJETIVO:El objetivo de este estudio es evaluar el valor pron&#xf3;stico de alcanzar el estado ypN0 tras la terapia neoadyuvante en pacientes con c&#xe1;ncer rectal localmente avanzado, comparando los resultados de supervivencia entre los grupos N0 natural, N0 en estadio inferior y ypN + .DISE&#xd1;O:Realizamos un an&#xe1;lisis post hoc del ensayo FOWARC, empleando el an&#xe1;lisis de supervivencia de Kaplan-Meier y modelos de regresi&#xf3;n de Cox para evaluar la supervivencia global, la supervivencia libre de enfermedad y la supervivencia libre de recidiva locorregional.ENTORNO:El ensayo multic&#xe9;ntrico y aleatorizado de fase III FOWARC se llev&#xf3; a cabo en 15 hospitales de China, respetando las normas &#xe9;ticas.PACIENTES:Nuestra cohorte incluy&#xf3; a 449 pacientes con c&#xe1;ncer rectal localmente avanzado que se sometieron a quimiorradioterapia neoadyuvante seguida de extirpaci&#xf3;n mesorrectal total.INTERVENCIONES:Quimiorradioterapia neoadyuvante seguida de extirpaci&#xf3;n mesorrectal total.PRINCIPALES MEDIDAS DE RESULTADO:El criterio de valoraci&#xf3;n principal fue la supervivencia global a 5 a&#xf1;os, y los criterios de valoraci&#xf3;n secundarios fueron la supervivencia libre de enfermedad a 3 a&#xf1;os y la supervivencia libre de recidiva locorregional a 3 a&#xf1;os.RESULTADOS:La supervivencia global a 5 a&#xf1;os para los grupos N0 natural y N0 en estadio inferior fue del 88 % y del 89 %, respectivamente, significativamente superior al 73 % observado en el grupo ypN + ( p = 0,0034). La tasa de respuesta patol&#xf3;gica completa fue notablemente inferior en el grupo ypN + . El an&#xe1;lisis multivariable mostr&#xf3; que el estadio ypN era un factor pron&#xf3;stico independiente para la supervivencia global.LIMITACIONES:El dise&#xf1;o retrospectivo del estudio puede introducir sesgos potenciales en la selecci&#xf3;n de pacientes y la estadificaci&#xf3;n preoperatoria.CONCLUSIONES:Alcanzar el estado ypN0 mediante quimiorradioterapia neoadyuvante mejora significativamente la supervivencia en pacientes con c&#xe1;ncer rectal localmente avanzado, independientemente del estado ypT o cN. Este estado no solo sirve como factor pron&#xf3;stico independiente, sino que tambi&#xe9;n puede ayudar a orientar estrategias de tratamiento posoperatorio individualizadas y basadas en hip&#xf3;tesis. (AI-generated translation ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Haigui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Human Microbiome and Chronic Diseases at Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Jingrong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Jinlin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhenghua</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peisi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Junyi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ziming</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Zixiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Ze</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gan</LastName><ForeName>Yingguo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Mingzhe</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Tuoyang</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaoxia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Human Microbiome and Chronic Diseases at Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Huichuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Human Microbiome and Chronic Diseases at Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Binbin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jinxin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2089-7084</Identifier><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yanxin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5200-3997</Identifier><AffiliationInfo><Affiliation>Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Institute of Gastroenterology, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01211210</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>2023A04J1817, JL</GrantID><Agency>the Science and Technology Program of Guangzhou</Agency><Country/></Grant><Grant><GrantID>1010CG(2022)-02, MH</GrantID><Agency>the Sixth Affiliated Hospital of Sun Yat-sen University Clinical Research-'1010' Program</Agency><Country/></Grant><Grant><GrantID>A2023094, JL</GrantID><Agency>the Medical Scientific Research Foundation of Guangdong Province</Agency><Country/></Grant><Grant><GrantID>No. R2021217202512965, YL</GrantID><Agency>the Excellent Talent Training Project of the Sixth Affiliated Hospital of Sun Yat-sen University</Agency><Country/></Grant><Grant><GrantID>No. 2022JBGS07, YL</GrantID><Agency>the Scientific Research Project of the Sixth Affiliated Hospital of Sun Yat-sen University</Agency><Country/></Grant><Grant><GrantID>2022007, MH; 2025006&#xef;&#xbc;&#x152;YL</GrantID><Agency>the Fundamental Research Funds for the Central Universities, Sun Yat-sen University</Agency><Country/></Grant><Grant><GrantID>2020B1111170004</GrantID><Agency>the Program of Introducing Talents of Discipline to Universities, the Program of Guangdong Provincial Clinical Research Center for Digestive Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>Q573I9DVLP</RegistryNumber><NameOfSubstance UI="D002955">Leucovorin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C410216">Folfox protocol</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002955" MajorTopicYN="N">Leucovorin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059186" MajorTopicYN="N">Chemoradiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="Y">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FOWARC clinical trial</Keyword><Keyword MajorTopicYN="N">Locally advanced rectal cancer</Keyword><Keyword MajorTopicYN="N">Neoadjuvant therapy</Keyword><Keyword MajorTopicYN="N">Nodal status</Keyword><Keyword MajorTopicYN="N">Tumor downstaging</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40626521</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003846</ArticleId><ArticleId IdType="pii">00003453-990000000-00997</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koukourakis IM, Kouloulias V, Tiniakos D, Georgakopoulos I, Zygogianni A. Current status of locally advanced rectal cancer therapy and future prospects. Crit Rev Oncol Hematol. 2023;186:103992.</Citation></Reference><Reference><Citation>Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229&#x2013;263.</Citation></Reference><Reference><Citation>Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12&#x2013;49.</Citation></Reference><Reference><Citation>Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:17&#x2013;48.</Citation></Reference><Reference><Citation>Zheng RS, Chen R, Han BF, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46:221&#x2013;231.</Citation></Reference><Reference><Citation>Wilkinson N. Management of rectal cancer. Surg Clin North Am. 2020;100:615&#x2013;628.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Adam M, et al. NCCN Guidelines&#xae; Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:366&#x2013;375.</Citation></Reference><Reference><Citation>Chen P-J, Wang L, Sun T-T, . Total neoadjuvant treatment for MRI-stratified high-risk rectal cancer: a single-center, single-arm, prospective Phase II trial (PKUCH-R02). Gastroenterol Rep. 2023;11:goad017.</Citation></Reference><Reference><Citation>Knippen S, Hildebrandt G, Putz F, Goss&#xe9; LL, Ritz J-P, Duma M-N. Assessing the practice of total neoadjuvant therapy for rectal cancer: an online survey among radiation oncology departments in Germany and German-speaking regions of Austria and Switzerland. Clin Exp Med. 2024;24:242.</Citation></Reference><Reference><Citation>Viola Malet M; LATAM collaborative colorectal surgery consortium. Short-term surgical outcomes of rectal adenocarcinoma surgical treatment in Latin America: a multicenter, retrospective assessment in 49 centers from 12 countries. Int J Colorectal Dis. 2024;39:210.</Citation></Reference><Reference><Citation>Coraglio MF, Eleta MA, Kujaruk MR, et al. Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer. World J Surg Oncol. 2020;18:313.</Citation></Reference><Reference><Citation>Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J Clin Oncol. 2016;34:3300&#x2013;3307.</Citation></Reference><Reference><Citation>Zhang J, Chi P, Shi L, . Neoadjuvant modified infusional fluorouracil, leucovorin, and oxaliplatin with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: updated results of the FOWARC study after a median follow-up of 10 years. J Clin Oncol. 2024;43:633&#x2013;640.</Citation></Reference><Reference><Citation>Li W-C, Zhao J-K, Feng W-Q, et al. Retrospective research of neoadjuvant therapy on tumor-downstaging, post-operative complications, and prognosis in locally advanced rectal cancer. World J Gastrointest Surg. 2021;13:267&#x2013;278.</Citation></Reference><Reference><Citation>Quah H-M, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57&#x2013;64.</Citation></Reference><Reference><Citation>Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770&#x2013;1776.</Citation></Reference><Reference><Citation>Kim NK, Baik SH, Seong JS, et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg. 2006;244:1024&#x2013;1030.</Citation></Reference><Reference><Citation>Haynes AB, You YN, Hu C-Y, et al. Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: analysis of Surveillance, Epidemiology, and End Results&#x2014;Medicare data, 1998-2007. Cancer. 2014;120:1162&#x2013;1170.</Citation></Reference><Reference><Citation>Wen B, Zhang L, Wang C, et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy. Radiat Oncol. 2015;10:124.</Citation></Reference><Reference><Citation>Bipat S, Glas AS, Slors FJM, Zwinderman AH, Bossuyt PMM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging&#x2014;a meta-analysis. Radiology. 2004;232:773&#x2013;783.</Citation></Reference><Reference><Citation>Chen HT, Xu GQ, Teng XD, Chen YP, Chen LH, Li YM. Diagnostic accuracy of endoscopic ultrasonography for rectal neuroendocrine neoplasms. World J Gastroenterol. 2014;20:10470&#x2013;10477.</Citation></Reference><Reference><Citation>Attenberger UI, Pilz LR, Morelli JN, et al. Multi-parametric MRI of rectal cancer&#x2014;do quantitative functional MR measurements correlate with radiologic and pathologic tumor stages? Eur J Radiol. 2014;83:1036&#x2013;1043.</Citation></Reference><Reference><Citation>Nougaret S, Rouanet P, Molinari N, et al. MR volumetric measurement of low rectal cancer helps predict tumor response and outcome after combined chemotherapy and radiation therapy. Radiology. 2012;263:409&#x2013;418.</Citation></Reference><Reference><Citation>Giusti S, Buccianti P, Castagna M, et al. Preoperative rectal cancer staging with phased-array MR. Radiat Oncol. 2012;7:29.</Citation></Reference><Reference><Citation>Kim SH, Lee JM, Hong SH, et al. Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy. Radiology. 2009;253:116&#x2013;125.</Citation></Reference><Reference><Citation>O&#x2019;Neill BDP, Salerno G, Thomas K, Tait DM, Brown G. MR vs CT imaging: low rectal cancer tumour delineation for three-dimensional conformal radiotherapy. Br J Radiol. 2009;82:509&#x2013;513.</Citation></Reference><Reference><Citation>O&#x2019;Neill BDP, Brown G, Heald RJ, Cunningham D, Tait DM. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol. 2007;8:625&#x2013;633.</Citation></Reference><Reference><Citation>Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2009;74:673&#x2013;688.</Citation></Reference><Reference><Citation>Deng Y, Chi P, Lan P, et al. Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial. J Clin Oncol. 2019;37:3223&#x2013;3233.</Citation></Reference><Reference><Citation>Li X-T, Sun Y-S, Tang L, Cao K, Zhang X-Y. Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis. Colorectal Dis. 2015;17:O129&#x2013;O135.</Citation></Reference><Reference><Citation>Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479&#x2013;2516.</Citation></Reference><Reference><Citation>Bosset JF, Calais G, Mineur L, et al.; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184&#x2013;190.</Citation></Reference><Reference><Citation>Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200&#x2013;207.</Citation></Reference><Reference><Citation>Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25:1356&#x2013;1362.</Citation></Reference><Reference><Citation>Verheij FS, Omer DM, Williams H, et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42:500&#x2013;506.</Citation></Reference><Reference><Citation>Dijkstra EA, Zwart WH, Nilsson PJ, et al.; collaborative investigators. The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer&#x2014;results from the RAPIDO trial. ESMO Open. 2023;8:101158.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39918199</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Impact of Low Ligation on Bowel Perfusion and Anastomotic Leakage in Minimally Invasive Rectal Cancer Surgery: A Post Hoc Analysis of a Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>544</StartPage><EndPage>552</EndPage><MedlinePgn>544-552</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003669</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Whether the level of the inferior mesenteric artery ligation affects the incidence of anastomotic leakage remains unclear.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the impact of the level of inferior mesenteric artery ligation on blood flow to the anastomotic site and the incidence of anastomotic leakage using indocyanine green fluorescence imaging.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A post hoc analysis of the EssentiAL trial.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">This study was conducted at 41 tertiary referral centers in Japan.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">A total of 839 patients with rectal cancer (&lt;12&#x2009;cm from the anal verge) were included.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">The incidence of anastomotic leakage and perfusion status were compared between the high and low ligation groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median fluorescence time was similar at 25 seconds in both groups (p = 0.74). Although no statistical difference was noted, the high ligation group was more likely to have greater outliers in fluorescence time compared to the low ligation group. The high ligation group demonstrated higher poor perfusion rates than the low ligation group (2.8% vs 1.5%). In the high ligation group, anastomotic leakage occurred in 1 case of poor perfusion where additional resection was not performed by the surgeon's intraoperative judgment. In addition, the additional resection rate nearly doubled with the use of indocyanine green fluorescence imaging. After propensity score matching (129 patients per group), the overall anastomotic leakage rate was 13.2% in the high ligation group and 10.9% in the low ligation group ( p = 0.57).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study was a post hoc analysis, the sample size was small, and the anastomosis methods varied.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The level of inferior mesenteric artery ligation did not affect blood flow at the anastomotic site or the incidence of anastomotic leakage statistically, but assessing bowel perfusion using indocyanine green fluorescence imaging can offer clinical benefits, optimizing patient outcomes. See Video Abstract .</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">The Japan Registry of Clinical Trials (jRCTs-CRB3180007), the Japanese Clinical Trials Registry (UMIN-CTR000030240).</AbstractText><AbstractText Label="IMPACTO DE LA LIGADURA BAJA EN LA PERFUSIN INTESTINAL Y LA FUGA ANASTOMTICA EN LA CIRUGA MNIMAMENTE INVASIVA DEL CNCER RECTAL UN ANLISIS POST HOC DE UN ENSAYO CONTROLADO ALEATORIZADO" NlmCategory="UNASSIGNED">ANTECEDENTES:No est&#xe1; claro si el nivel de la ligadura de la arteria mesent&#xe9;rica inferior afecta la incidencia de fuga anastom&#xf3;tica.OBJETIVO:Evaluar el impacto del nivel de ligadura de la arteria mesent&#xe9;rica inferior en el flujo sangu&#xed;neo al sitio de la anastomosis y la incidencia de fuga anastom&#xf3;tica mediante im&#xe1;genes de fluorescencia con verde de indocianina.DISE&#xd1;O:An&#xe1;lisis post hoc del ensayo EssentiAL.ESCENARIO:Este estudio se realiz&#xf3; en 41 centros de referencia terciarios en Jap&#xf3;n.PACIENTES:839 pacientes con c&#xe1;ncer rectal (&lt;12 cm desde el m&#xe1;rgen anal).PRINCIPALES MEDIDAS DE RESULTADOS:Se compararon la incidencia de fuga anastom&#xf3;tica y el estado de perfusi&#xf3;n entre los grupos de ligadura alta y baja.RESULTADOS:El tiempo de fluorescencia medio fue similar a 25 segundos en ambos grupos (p = 0.74). Aunque no se observ&#xf3; ninguna diferencia estad&#xed;stica, el grupo de ligadura alta tuvo m&#xe1;s probabilidades de tener mayores valores at&#xed;picos en el tiempo de fluorescencia en comparaci&#xf3;n con el grupo de ligadura baja. El grupo de ligadura alta demostr&#xf3; tasas de perfusi&#xf3;n deficiente m&#xe1;s altas que el grupo de ligadura baja (2.8 % frente a 1.5 %). En el grupo de ligadura alta, se produjo una fuga anastom&#xf3;tica en un caso de perfusi&#xf3;n deficiente en el que no se realiz&#xf3; una resecci&#xf3;n adicional seg&#xfa;n el criterio intraoperatorio del cirujano. Adem&#xe1;s, la tasa de resecci&#xf3;n adicional casi se duplic&#xf3; con el uso de im&#xe1;genes de fluorescencia con verde de indocianina. Despu&#xe9;s de la comparaci&#xf3;n por puntaje de propensi&#xf3;n (129 pacientes por grupo), la tasa general de fuga anastom&#xf3;tica fue del 13.2 % en el grupo de ligadura alta y del 10.9 % en el grupo de ligadura baja ( p = 0.57).LIMITACIONES:Este estudio fue un an&#xe1;lisis post hoc, el tama&#xf1;o de la muestra fue peque&#xf1;o y los m&#xe9;todos de anastomosis variaron.CONCLUSIONES:El nivel de ligadura de la arteria mesent&#xe9;rica inferior no afect&#xf3; estad&#xed;sticamente el flujo sangu&#xed;neo en el sitio de la anastomosis ni la incidencia de fuga anastom&#xf3;tica, pero la evaluaci&#xf3;n de la perfusi&#xf3;n intestinal mediante im&#xe1;genes de fluorescencia con verde de indocianina puede ofrecer beneficios cl&#xed;nicos, optimizando los resultados del paciente. (Traducci&#xf3;n-Dr. Jorge Silva Velazco)REGISTRO DEL ENSAYO:Registro japon&#xe9;s de ensayos cl&#xed;nicos (jRCTs-CRB3180007), Registro japon&#xe9;s de ensayos cl&#xed;nicos (UMIN-CTR000030240).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Kei</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4646-667</Identifier><AffiliationInfo><Affiliation>Division of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7187-3664</Identifier><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Kansai Medical University, Hirakata, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotake</LastName><ForeName>Masanori</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kouseiren Takaoka Hospital, Takaoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noura</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Toyonaka Municipal Hospital, Toyonaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suwa</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgery, Yokosuka Kyosai Hospital, Yokosuka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tei</LastName><ForeName>Mitsuyoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Osaka Rosai Hospital, Sakai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Yoshinao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Southern TOHOKU Research Institute for Neuroscience, Southern TOHOKU General Hospital, Koriyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munakata</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Ikeda City Hospital, Ikeda, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matoba</LastName><ForeName>Shuichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Toranomon Hospital, Minato, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamagishi</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Fujisawa City Hospital, Fujisawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasui</LastName><ForeName>Masayoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, NHO Osaka National Hospital, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozawa</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiozawa</LastName><ForeName>Manabu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kitasato University Kitasato Institute Hospital, Minato, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yabuno</LastName><ForeName>Taichi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nitta</LastName><ForeName>Toshikatsu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Surgery Gastroenterological Center, Medico Shunju Shiroyama Hospital, Habikino, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Shuji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Surgery, Gastrointestinal Center, Yokohama Shin-Midori General Hospital, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, Kitakyushu General Hospital, Kitakyushu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery (First Surgery), University of Yamanashi Hospital, Yamanashi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Suguru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Fukuoka University Hospital, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Goutaro</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgery, Mitsuwadai General Hospital, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Nagoya City University Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawai</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Lower Gastrointestinal Surgery, Kansai Rosai Hospital, Amagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furuhata</LastName><ForeName>Tomohisa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Digestive Disease Center, St. Marianna University Toyoko Hospital, Kawasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonooka</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Esophago-Gastrointestinal Surgery, Chiba Cancer Center, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanazawa</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Shimane Prefectural Central Hospital, Izumo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuriu</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University, Bunkyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinjo</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Digestive and General Surgery, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Hideo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgery, Tama Medical Center, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uemura</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Toshifumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Surgery, Toyama City Hospital, Toyama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kindai University Hospital, Osakasayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Masataka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Lower GI, Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takemasa</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>On the behalf of EssentiAL Trial Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IX6J1063HV</RegistryNumber><NameOfSubstance UI="D007208">Indocyanine Green</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="Y">Anastomotic Leak</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008026" MajorTopicYN="N">Ligation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007208" MajorTopicYN="N">Indocyanine Green</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017537" MajorTopicYN="Y">Mesenteric Artery, Inferior</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019060" MajorTopicYN="Y">Minimally Invasive Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="Y">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061848" MajorTopicYN="N">Optical Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anastomotic leak</Keyword><Keyword MajorTopicYN="N">Blood perfusion</Keyword><Keyword MajorTopicYN="N">Indocyanine green</Keyword><Keyword MajorTopicYN="N">Left colic artery</Keyword><Keyword MajorTopicYN="N">Low ligation</Keyword><Keyword MajorTopicYN="N">Rectal cancer</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Kanazawa</LastName><ForeName>Akiyoshi</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ichikawa</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Goutaro</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Hideo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suwa</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagahara</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takemasa</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ueda</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kimura</LastName><ForeName>Kei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Keitaro</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawai</LastName><ForeName>Kenji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munakata</LastName><ForeName>Koji</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uemura</LastName><ForeName>Mamoru</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiozawa</LastName><ForeName>Manabu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Masahiko</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kotake</LastName><ForeName>Masanori</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Masataka</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yasui</LastName><ForeName>Masayoshi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozawa</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawamura</LastName><ForeName>Mikio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tei</LastName><ForeName>Mitsuyoshi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagata</LastName><ForeName>Naoki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamagishi</LastName><ForeName>Shigeru</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noura</LastName><ForeName>Shingo</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matoba</LastName><ForeName>Shuichiro</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saito</LastName><ForeName>Shuji</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Suguru</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yabuno</LastName><ForeName>Taichi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kato</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinjo</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furuhata</LastName><ForeName>Tomohisa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonooka</LastName><ForeName>Toru</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Toshifumi</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nitta</LastName><ForeName>Toshikatsu</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirano</LastName><ForeName>Yasumitsu</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuriu</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Takano</LastName><ForeName>Yoshinao</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suwa</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>2</Month><Day>7</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39918199</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003669</ArticleId><ArticleId IdType="pii">00003453-990000000-00865</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Park JS, Choi GS, Kim SH, et al. Multicenter analysis of risk factors for anastomotic leakage after laparoscopic rectal cancer excision: the Korean laparoscopic colorectal surgery study group. Ann Surg. 2013;257:665&#x2013;671.</Citation></Reference><Reference><Citation>Nayeri M, Iskander O, Tabchouri N, et al. Low tie compared to high tie vascular ligation of the inferior mesenteric artery in rectal cancer surgery decreases postoperative complications without affecting overall survival. Anticancer Res. 2019;39:4363&#x2013;4370.</Citation></Reference><Reference><Citation>Kudszus S, Roesel C, Schachtrupp A, H&#xf6;er JJ. Intraoperative laser fluorescence angiography in colorectal surgery: a noninvasive analysis to reduce the rate of anastomotic leakage. Langenbecks Arch Surg. 2010;395:1025&#x2013;1030.</Citation></Reference><Reference><Citation>Watanabe J, Ishibe A, Ohya H, et al. Evaluating the effect of intraoperative near-infrared observation on anastomotic leakage after stapled side-to-side anastomosis in colon cancer surgery using propensity score matching. Dis Colon Rectum. 2021;64:1542&#x2013;1550.</Citation></Reference><Reference><Citation>Watanabe J, Takemasa I, Kotake M, et al.; EssentiAL Trial Group. Blood perfusion assessment by indocyanine green fluorescence imaging for minimally invasive rectal cancer surgery (EssentiAL trial): a randomized clinical trial. Ann Surg. 2023;278:e688&#x2013;e694.</Citation></Reference><Reference><Citation>Bonnet S, Berger A, Hentati N, et al. High tie versus low tie vascular ligation of the inferior mesenteric artery in colorectal cancer surgery: impact on the gain in colon length and implications on the feasibility of anastomoses. Dis Colon Rectum. 2012;55:515&#x2013;521.</Citation></Reference><Reference><Citation>Adachi Y, Kakisako K, Sato K, Shiraishi N, Miyahara M, Kitano S. Factors influencing bowel function after low anterior resection and sigmoid colectomy. Hepatogastroenterology. 2000;47:155&#x2013;158.</Citation></Reference><Reference><Citation>Kong M, Chen H, Xin Y, Jiang Y, Han Y, Sheng H. High ligation of the inferior mesenteric artery and anastomotic leakage in anterior resection for rectal cancer: a systematic review and meta-analysis of randomized controlled trial studies. Colorectal Dis. 2021;23:614&#x2013;624.</Citation></Reference><Reference><Citation>Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal, appendiceal, and anal carcinoma: the 3d English edition [Secondary Publication]. J Anus Rectum Colon. 2019;3:175&#x2013;195.</Citation></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150&#x2013;161.</Citation></Reference><Reference><Citation>Fujii S, Ishibe A, Ota M, et al. Short-term and long-term results of a randomized study comparing high tie and low tie inferior mesenteric artery ligation in laparoscopic rectal anterior resection: subanalysis of the HTLT (high tie vs. low tie) study. Surg Endosc. 2019;33:1100&#x2013;1110.</Citation></Reference><Reference><Citation>Zhou J, Zhang S, Huang J, et al. Accurate low ligation of inferior mesenteric artery and root lymph node dissection according to different vascular typing in laparoscopic radical resection of rectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi. 2018;21:46&#x2013;52.</Citation></Reference><Reference><Citation>Matsuda K, Hotta T, Takifuji K, et al. Randomized clinical trial of defaecatory function after anterior resection for rectal cancer with high versus low ligation of the inferior mesenteric artery. Br J Surg. 2015;102:501&#x2013;508.</Citation></Reference><Reference><Citation>Mari GM, Crippa J, Cocozza E, et al. Low ligation of inferior mesenteric artery in laparoscopic anterior resection for rectal cancer reduces genitourinary dysfunction: results from a randomized controlled trial (HIGHLOW trial). Ann Surg. 2019;269:1018&#x2013;1024.</Citation></Reference><Reference><Citation>Hajibandeh S, Hajibandeh S, Maw A. Meta-analysis and trial sequential analysis of randomized controlled trials comparing high and low ligation of the inferior mesenteric artery in rectal cancer surgery. Dis Colon Rectum. 2020;63:988&#x2013;999.</Citation></Reference><Reference><Citation>Watanabe J, Ishibe A, Suwa Y, et al. Indocyanine green fluorescence imaging to reduce the risk of anastomotic leakage in laparoscopic low anterior resection for rectal cancer: a propensity score-matched cohort study. Surg Endosc. 2020;34:202&#x2013;208.</Citation></Reference><Reference><Citation>Emile SH, Dourado J, Rogers P, et al. Splenic flexure mobilization in left-sided colonic and rectal resections: a meta-analysis and meta-regression of factors associated with anastomotic leak and complications. Colorectal Dis. 2024;26:1332&#x2013;1345.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38830268</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Effect of Sublay Preventive Mesh for Terminal Colostomy on Symptoms and Quality of Life in Patients With Parastomal Hernia: A Post Hoc Analysis of the GRECCAR 7 Cohort.</ArticleTitle><Pagination><StartPage>1210</StartPage><EndPage>1216</EndPage><MedlinePgn>1210-1216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003257</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent randomized clinical trials and meta-analyses confirm that the use of a prophylactic mesh does not significantly reduce the parastomal hernia rate. Data about the benefits of these meshes concerning the symptoms of parastomal hernia are lacking in the existing literature.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to perform a post hoc analysis of the patients presenting parastomal hernia from the GRECCAR 7 (Groupe de recherche sur la chirurgie du cancer du rectum) randomized clinical trials cohort on whether the presence or the absence of the mesh influenced the symptoms, the quality of life, and complications of patients with parastomal hernias.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We studied the parastomal hernia-related symptoms among the 2 groups of the GRECCAR 7 randomized clinical trial, with or without prophylactic mesh at the time of the index surgery.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Data were retrospectively extracted and analyzed from the GRECCAR 7 database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients diagnosed with a parastomal hernia during the 2 years of the GRECCAR 7 study.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Several prospectively collected data about the symptoms were studied among this population. We also studied the average interval between parastomal hernia repair surgery and both index surgery and diagnosis of parastomal hernia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 199 patients included in the GRECCAR study, 36 patients (35.6%) in the nonmesh group and 33 patients (33.7%) in the mesh group were diagnosed with clinical and/or radiological parastomal hernia at 2-year follow-up, without a statistically significant difference ( p = 0.89). None of the studied symptoms showed any statistically significant difference between the groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study relies on a relatively small number of patients, and although data were prospectively collected, we lacked some details about the categorization of parastomal hernias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We believe that the use of a prosthetic mesh in a sublay position to prevent parastomal hernia in terminal end colostomy patients should no longer be recommended. See Video Abstract .</AbstractText><AbstractText Label="EFECTO DE LA MALLA PREVENTIVA RETROMUSCULAR PARA COLOSTOMA TERMINAL CON RESPECTO A LOS SNTOMAS Y LA CALIDAD DE VIDA EN PACIENTES CON HERNIA PARAESTOMAL UN ANLISIS POSTHOC DE LA COHORTE GRECCAR" NlmCategory="UNASSIGNED">ANTECEDENTES:Los recientes metaan&#xe1;lisis y ensayos cl&#xed;nicos aleatorizados confirman que el uso de una malla profil&#xe1;ctica no reduce significativamente la tasa de hernia paraestomal. En la literatura existente faltan datos sobre los beneficios de estas mallas en relaci&#xf3;n con los s&#xed;ntomas de la hernia paraestomal.OBJETIVO:El objetivo de este estudio fue realizar un an&#xe1;lisis post-hoc de los pacientes que presentaron hernia paraestomal de la cohorte de 7 ensayos cl&#xed;nicos aleatorizados GRECCAR sobre si la presencia o ausencia de la malla influy&#xf3; en los s&#xed;ntomas, la calidad de vida y las complicaciones de los pacientes con hernias paraestomales.DISE&#xd1;O:Estudiamos los s&#xed;ntomas relacionados con la hernia paraestomal entre los dos grupos del ensayo cl&#xed;nico aleatorizado GRECCAR 7, con o sin malla profil&#xe1;ctica en el momento de la cirug&#xed;a &#xed;ndice.AJUSTES:Los datos fueron extra&#xed;dos y analizados de manera retrospectiva de la base de datos GRECCAR 7.PACIENTES:Pacientes diagnosticados con hernia paraestomal durante los dos a&#xf1;os del estudio GRECCAR 7.PRINCIPALES MEDIDAS DE RESULTADO:Se estudiaron varios datos recopilados de manera prospectiva sobre los s&#xed;ntomas en esta poblaci&#xf3;n. Tambi&#xe9;n estudiamos el intervalo promedio entre la cirug&#xed;a reparadora de la hernia paraestomal as&#xed; como tambi&#xe9;n la cirug&#xed;a &#xed;ndice como el diagn&#xf3;stico de la hernia paraestomal.RESULTADOS:De entre los 199 pacientes incluidos en el estudio GRECCAR, 36 pacientes (35,6%) fueron diagnosticados con hernia paraestomal de manera cl&#xed;nica y/o radiol&#xf3;gica en el grupo sin malla a los 2 a&#xf1;os de seguimiento y 33 (33,7%) en el grupo con malla, sin diferencia estad&#xed;sticamente significativa ( p = 0,89). Ninguno de los s&#xed;ntomas estudiados mostr&#xf3; diferencias estad&#xed;sticamente significativas entre los grupos.LIMITACIONES:Este estudio se basa en un n&#xfa;mero relativamente peque&#xf1;o de pacientes y, aunque los datos fueron recopilados de forma prospectiva, nos faltaron algunos detalles sobre la categorizaci&#xf3;n de las hernias paraestomales.CONCLUSIONES:Creemos que ya no se debe recomendar el uso de una malla prot&#xe9;sica en posici&#xf3;n retromuscular para prevenir la hernia paraestomal en pacientes con colostom&#xed;a terminal. (Traducci&#xf3;n-Dr. Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Martin M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theuil</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demattei</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudhomme</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GRECCAR Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013526" MajorTopicYN="Y">Surgical Mesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003125" MajorTopicYN="Y">Colostomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069290" MajorTopicYN="N">Incisional Hernia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054047" MajorTopicYN="N">Surgical Stomas</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006555" MajorTopicYN="N">Hernia, Ventral</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38830268</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003257</ArticleId><ArticleId IdType="pii">00003453-202409000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carne P, Robertson G, Frizelle F. Parastomal hernia. Br J Surg. 2003;90:1306&#x2013;1307.</Citation></Reference><Reference><Citation>National Bowel Cancer Audit. Annual report 2021. An audit of the care received by people with bowel cancer in England and Wales. https://www.nboca.org.uk/content/uploads/2022/02/NBOCA-2021-AR-Final.pdf . Accessed August 31, 2023.</Citation></Reference><Reference><Citation>Glasgow SC, Dharmarajan S. Parastomal hernia: avoidance and treatment in the 21st century. Clin Colon Rectal Surg. 2016;29:277&#x2013;284.</Citation></Reference><Reference><Citation>Londono-Schimmer E, Leong A, Phillips R. Life table analysis of stomal complications following colostomy. Dis Colon Rectum. 1994;37:916&#x2013;920.</Citation></Reference><Reference><Citation>Ripoche J, Basurko C, Fabbro-Perray P, Prudhomme M. Parastomal hernia. A study of the French federation of ostomy patients. J Visc Surg. 2011;148:e435&#x2013;e441.</Citation></Reference><Reference><Citation>Antoniou S, Agresta F, Alamino JG, et al. European Hernia Society guidelines on prevention and treatment of parastomal hernias. Hernia. 2018;22:183&#x2013;198.</Citation></Reference><Reference><Citation>ACPGBI Parastomal Hernia Group. Prevention and treatment of parastomal hernia: a position statement on behalf of the Association of Coloproctology of Great Britain and Ireland. Colorectal Dis. 2018;20(suppl 2):5&#x2013;19.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. Interventional procedures guidance [IPG654]. https://www.nice.org.uk/guidance/ipg654/resources/reinforcement-of-a-permanent-stoma-with-a-synthetic-or-biological-mesh-to-prevent-a-parastomal-hernia-pdf-1899874164041413 . Accessed August 31, 2023.</Citation></Reference><Reference><Citation>Aslam M, Rubio-Perez I, Smart N, Singh B; Committee ESoCE. A survey on practices for parastomal hernia prevention and repair among ESCP surgeons. Hernia. 2019;23:825&#x2013;828.</Citation></Reference><Reference><Citation>Prudhomme M, Rullier E, Lakkis Z, et al.; GRECCAR research group. End colostomy with or without mesh to prevent a parastomal hernia (GRECCAR 7): a prospective, randomized, double blinded, multicentre trial. Ann Surg. 2021;274:928&#x2013;934.</Citation></Reference><Reference><Citation>Odensten C, Strig&#xe5;rd K, Ruteg&#xe5;rd J, et al. Use of prophylactic mesh when creating a colostomy does not prevent parastomal hernia: a randomized controlled trial&#x2014;STOMAMESH. Ann Surg. 2019;269:427&#x2013;431.</Citation></Reference><Reference><Citation>Prudhomme M, Fabbro-Peray P, Rullier E, Occean BV, Bertrand MM. Meta-analysis and systematic review of the use of a prosthetic mesh for prevention of parastomal hernia. Ann Surg. 2021;274:20&#x2013;28.</Citation></Reference><Reference><Citation>Serra-Aracil X, Bombardo-Junca J, Moreno-Matias J, et al. Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia. Ann Surg. 2009;249:583&#x2013;587.</Citation></Reference><Reference><Citation>Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K. Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial. Colorectal Dis. 2015;17:O191&#x2013;O197.</Citation></Reference><Reference><Citation>L&#xf3;pez-Cano M, Lozoya-Trujillo R, Quiroga S, et al. Use of a prosthetic mesh to prevent parastomal hernia during laparoscopic abdominoperineal resection: a randomized controlled trial. Hernia. 2012;16:661&#x2013;667.</Citation></Reference><Reference><Citation>L&#xf3;pez-Cano M, Serra-Aracils X, Mora L, et al. Preventing parastomal hernia using a modified Sugarbaker technique with composite mesh during laparoscopic abdominoperineal resection. Ann Surg. 2016;264:923&#x2013;928.</Citation></Reference><Reference><Citation>J&#xe4;nes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. Br J Surg. 2004;91:280&#x2013;282.</Citation></Reference><Reference><Citation>Fleshman JW, Beck DE, Hyman N, Wexner SD, Bauer J, George V; PRISM Study Group. A prospective, multicenter, randomized, controlled study of non-cross-linked porcine acellular dermal matrix fascial sublay for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. Dis Colon Rectum. 2014;57:623&#x2013;631.</Citation></Reference><Reference><Citation>Vierimaa M, Klintrup K, Biancari F, et al. Prospective, randomized study on the use of a prosthetic mesh for prevention of parastomal hernia of permanent colostomy. Dis Colon Rectum. 2015;58:943&#x2013;949.</Citation></Reference><Reference><Citation>M&#xe4;k&#xe4;r&#xe4;inen-Uhlb&#xe4;ck EJ, Klintrup KH, Vierimaa MT, et al. Prospective, randomized study on the use of prosthetic mesh to prevent a parastomal hernia in a permanent colostomy: results of a long-term follow-up. Dis Colon Rectum. 2020;63:678&#x2013;684.</Citation></Reference><Reference><Citation>Rajaretnam N, Smart NJ. To mesh or not to mesh&#x2014;the known unknowns of preventing parastomal hernias. Br J Surg. 2022;109:1&#x2013;2.</Citation></Reference><Reference><Citation>Prudhomme M, Alline M, Chauvat J, Fabbro-Perray P, Ripoche J, Bertrand MM; French Research Group of Rectal Cancer Surgery (GRECCAR). Primary prevention of peristomial hernias via parietal prostheses: a randomized, multicentric study (GRECCAR 7 trial). Dig Liver Dis. 2016;48:812&#x2013;816.</Citation></Reference><Reference><Citation>Prieto L, Thorsen H, Juul K. Development and validation of a quality of life questionnaire for patients with colostomy or ileostomy. Health Qual Life Outcomes. 2005;3:1&#x2013;10.</Citation></Reference><Reference><Citation>Marinez AC, Bock D, Carlsson E, et al. Stoma-related complications: a report from the Stoma-Const randomized controlled trial. Colorectal Dis. 2021;23:1091&#x2013;1101.</Citation></Reference><Reference><Citation>Marinez AC, Bock D, Erestam S, et al. Methods of colostomy construction: no effect on parastomal hernia rate: results from stoma-const&#x2014;a randomized controlled trial. Ann Surg. 2021;273:640&#x2013;647.</Citation></Reference><Reference><Citation>N&#xe4;verlo S, Gunnarsson U, Strig&#xe5;rd K, N&#xe4;svall P. Quality of life after end colostomy without mesh and with prophylactic synthetic mesh in sublay position: one-year results of the STOMAMESH trial. Int J Colorectal Dis. 2019;34:1591&#x2013;1599.</Citation></Reference><Reference><Citation>Brandsma H-T, Hansson BM, Aufenacker TJ, et al.; Dutch Prevent Study group. Prophylactic mesh placement during formation of an end-colostomy reduces the rate of parastomal hernia. Ann Surg. 2017;265:663&#x2013;669.</Citation></Reference><Reference><Citation>Conde-Mu&#xed;&#xf1;o R, D&#xed;ez JL, Mart&#xed;nez A, Huertas F, Segura I, Palma P. Preventing parastomal hernias with systematic intraperitoneal specifically designed mesh. BMC Surg. 2017;17:41.</Citation></Reference><Reference><Citation>Luo J, Singh D, Zhang F, et al. Comparison of the extraperitoneal and transperitoneal routes for permanent colostomy: a meta-analysis with RCTs and systematic review. World J Surg Oncol. 2022;20:82.</Citation></Reference><Reference><Citation>M&#xe4;k&#xe4;r&#xe4;inen-Uhlb&#xe4;ck E, Wiik H, K&#xf6;ssi J, Nikberg M, Ohtonen P, Rautio T. Chimney Trial: study protocol for a randomized controlled trial. Trials. 2019;20:652.</Citation></Reference><Reference><Citation>Liu Y, Fu X, Chen H, Yao Q. Surgical strategies for recurrent parastomal hernia after a primary repair with a Dynamesh(&#xae;) IPST mesh. Hernia. 2023;27:617&#x2013;621.</Citation></Reference><Reference><Citation>Chapman SJ, Wood B, Drake TM, Young N, Jayne DG. Systematic review and meta-analysis of prophylactic mesh during primary stoma formation to prevent parastomal hernia. Dis Colon Rectum. 2017;60:107&#x2013;115.</Citation></Reference><Reference><Citation>Hansson BM, Slater NJ, van der Velden AS, et al. Surgical techniques for parastomal hernia repair: a systematic review of the literature. Ann Surg. 2012;255:685&#x2013;695.</Citation></Reference><Reference><Citation>PROPHER Study Collaborating Group. The PROPHER Study: patient reported outcomes after parastomal hernia treatment&#x2014;a prospective international cohort study. Colorectal Dis. 2024;26:554&#x2013;563.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35239526</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Transanal Hemorrhoidal Dearterialization With Mucopexy Versus Vessel-Sealing Device Hemorrhoidectomy for Grade III to IV Hemorrhoids: Long-term Outcomes From the THDLIGA Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>e818</StartPage><EndPage>e825</EndPage><MedlinePgn>e818-e825</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002272</ELocationID><Abstract><AbstractText Label="BACKGROUND">Both transanal hemorrhoidal dearterialization and vessel-sealing device hemorrhoidectomy are safe for grade III to IV hemorrhoid treatment. Whether one of them is superior regarding long-term results remains unclear.</AbstractText><AbstractText Label="OBJECTIVE">To compare long-term results after transanal hemorrhoidal dearterialization and vessel-sealing device hemorrhoidectomy.</AbstractText><AbstractText Label="DESIGN">Multicenter randomized controlled trial.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at 6 centers.</AbstractText><AbstractText Label="PATIENTS">Patients &#x2265;18 years of age with grade III to IV hemorrhoids were included in the study.</AbstractText><AbstractText Label="INTERVENTIONS">Patients were randomly assigned to transanal hemorrhoidal dearterialization (n = 39) or vessel-sealing device hemorrhoidectomy (n = 41).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was hemorrhoid symptom recurrence assessed by a specific questionnaire 2 years postoperatively. Secondary outcomes included long-term complications, reoperations, fecal continence, and patient satisfaction and quality of life.</AbstractText><AbstractText Label="RESULTS">Five of the 80 patients included in the study were lost to follow-up. Thirty-six patients randomly assigned to transanal hemorrhoidal dearterialization and 39 patients randomly assigned to vessel-sealing device hemorrhoidectomy were included in the long-term analysis. The differences between mean baseline and mean 2-year score in the 2 groups were similar (-11.0, SD 3.8 vs -12.5, SD 3.6; p = 0.080). Three patients in the transanal hemorrhoidal dearterialization group underwent supplementary procedures for hemorrhoid symptoms, compared with none in the vessel-sealing device hemorrhoidectomy group ( p = 0.106). Four patients in the vessel-sealing hemorrhoidectomy group and none in the transanal hemorrhoidal dearterialization group experienced chronic opened wound ( p = 0.116).</AbstractText><AbstractText Label="LIMITATIONS">Lack of stratification for hemorrhoid grade and power calculation based on the main outcome trial but not on the end point of this long-term study.</AbstractText><AbstractText Label="CONCLUSIONS">Transanal hemorrhoidal dearterialization with mucopexy is associated with hemorrhoid symptom recurrence similar to vessel-sealing device hemorrhoidectomy at 2 years. See Video Abstract at http://links.lww.com/DCR/B933 .</AbstractText><AbstractText Label="REGISTRATION">Clinicaltrials.gov ; ID: NCT02654249.</AbstractText><AbstractText Label="DESARTERIALIZACIN HEMORROIDAL TRANSANAL CON MUCOPEXIA VERSUS HEMORROIDECTOMA CON DISPOSITIVO DE SELLADO DE VASOS PARA HEMORROIDES DE GRADO IIIIV RESULTADOS A LARGO PLAZO DEL ENSAYO CLNICO ALEATORIZADO THDLIGARCT">ANTECEDENTES:Tanto la desarterializaci&#xf3;n hemorroidal transanal como la hemorroidectom&#xed;a con dispositivo de sellado de vasos son seguras y bien toleradas para el tratamiento de las hemorroides de grado III-IV. La primera se asocia con una necesidad m&#xe1;s breve de analgesia posoperatoria que la hemorroidectom&#xed;a con dispositivo de sellado de vasos. No est&#xe1; claro si uno de ellos es superior con respecto a los resultados a largo plazo.OBJETIVO:El objetivo fue comparar los resultados a largo plazo despu&#xe9;s de la desarterializaci&#xf3;n hemorroidal transanal y la hemorroidectom&#xed;a con dispositivo de sellado de vasos.DISE&#xd1;O:Se realiz&#xf3; un ensayo cl&#xed;nico aleatorizado multic&#xe9;ntrico.AJUSTE:Este estudio se realiz&#xf3; en 6 centros.PACIENTES:Se incluyeron en el estudio pacientes de &#x2265;18 a&#xf1;os con hemorroides de grado III-IV.INTERVENCIONES:Los pacientes fueron asignados al azar a desarterializaci&#xf3;n hemorroidal transanal (n = 39) o hemorroidectom&#xed;a con dispositivo de sellado de vasos (n = 41).PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario fue la recurrencia de los s&#xed;ntomas de hemorroides evaluada mediante un cuestionario espec&#xed;fico 2 a&#xf1;os despu&#xe9;s de la operaci&#xf3;n. Los resultados secundarios incluyeron complicaciones a largo plazo, reoperaciones, continencia fecal, satisfacci&#xf3;n del paciente y calidad de vida.RESULTADOS:Cinco de los 80 pacientes incluidos en el estudio se perdieron durante el seguimiento. En el an&#xe1;lisis a largo plazo se incluyeron 36 pacientes aleatorizados a desarterializaci&#xf3;n hemorroidal transanal y 39 aleatorizados a hemorroidectom&#xed;a con dispositivo de sellado de vasos. Las diferencias entre la puntuaci&#xf3;n inicial media y la puntuaci&#xf3;n media a los 2 a&#xf1;os en los dos grupos fueron similares (-11,0, DE 3,8 frente a -12,5, DE 3,6; p = 0,080). Tres pacientes en el grupo de desarterializaci&#xf3;n hemorroidal transanal se sometieron a procedimientos complementarios por s&#xed;ntomas de hemorroides, en comparaci&#xf3;n con ninguno en el grupo de hemorroidectom&#xed;a con dispositivo de sellado de vasos (p = 0,106). Cuatro pacientes en el grupo de hemorroidectom&#xed;a con sellado de vasos y ninguno en el grupo de desarterializaci&#xf3;n hemorroidal transanal experimentaron herida abierta cr&#xf3;nica (p = 0,116). No se encontraron diferencias en cuanto a continencia fecal (p = 0,657), satisfacci&#xf3;n del paciente (p = 0,483) y calidad de vida.LIMITACIONES:No hay estratificaci&#xf3;n para el grado de hemorroides ni el c&#xe1;lculo del poder basado en el resultado principal del ensayo, pero no en el criterio de valoraci&#xf3;n de este estudio a largo plazo.CONCLUSIONES:La desarterializaci&#xf3;n hemorroidal transanal con mucopexia se asocia con una recurrencia de s&#xed;ntomas de hemorroides similar a la hemorroidectom&#xed;a con dispositivo de sellado de vasos a los dos a&#xf1;os. See Video Abstract at http://links.lww.com/DCR/B933 . (Traducci&#xf3;n- Dr. Francisco M. Abarca-Rendon )REGISTRO DE PRUEBA:Clinicaltrials.gov (NCT02654249).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trenti</LastName><ForeName>Loris</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, Bellvitge University Hospital, University of Barcelona and IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biondo</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, Bellvitge University Hospital, University of Barcelona and IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espin-Basany</LastName><ForeName>Eloy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, Vall d'Hebron University Hospital Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrios</LastName><ForeName>Oriana</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, Bellvitge University Hospital, University of Barcelona and IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Garcia</LastName><ForeName>Jose L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, Vall d'Hebron University Hospital Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landaluce-Olavarria</LastName><ForeName>Aitor</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Galdakao Usansolo Hospital, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bermejo-Marcos</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, La Princesa University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Martinez</LastName><ForeName>Maria T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Surgery, Valdeorras Hospital, Ourense, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alias Jimenez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Surgery, Rey Juan Carlos University Hospital, M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery, Galdakao Usansolo Hospital, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Adolfo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, La Princesa University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manso</LastName><ForeName>Maria B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Surgery, Rey Juan Carlos University Hospital, M&#xf3;stoles, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreisler</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, Bellvitge University Hospital, University of Barcelona and IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>THDLIGA-RCT Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02654249</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006484" MajorTopicYN="Y">Hemorrhoids</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061865" MajorTopicYN="Y">Hemorrhoidectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012007" MajorTopicYN="N">Rectum</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Frago</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fraccalvieri</LastName><ForeName>Domenico</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golda</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge University Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rey Juan Carlos University Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Currel</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tapiolas</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Vall d'Hebron University Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Garc&#xed;a</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Valdeorras Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Langara</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Galdakao Usansolo Hospital.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Miguel-Huguet</LastName><ForeName>Bernat</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Statistician and Data Manager of the Colorectal Unit) for the statistical analysis (Bellvitge University Hospital and IDIBELL).</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Ramon</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>financial department of the Bellvitge University Hospital.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35239526</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002272</ArticleId><ArticleId IdType="pii">00003453-202308000-00014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology. 1990;98:380&#x2013;386.</Citation></Reference><Reference><Citation>Lohsiriwat V. Hemorrhoids: from basic pathophysiology to clinical management. World J Gastroenterol. 2012;18:2009&#x2013;2017.</Citation></Reference><Reference><Citation>Jacobs D. Clinical practice. Hemorrhoids. N Engl J Med. 2014;371:944&#x2013;951.</Citation></Reference><Reference><Citation>Gallo G, Martellucci J, Sturiale A, et al. Consensus statement of the Italian Society of Colorectal Surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Coloproctol. 2020;24:145&#x2013;164.</Citation></Reference><Reference><Citation>Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids. Dis Colon Rectum. 2018;61:284&#x2013;292.</Citation></Reference><Reference><Citation>De Nardi P, Capretti G, Corsaro A, Staudacher C. A prospective, randomized trial comparing the short- and long-term results of Doppler-guided transanal hemorrhoid dearterialization with mucopexy versus excision hemorrhoidectomy for grade III hemorrhoids. Dis Colon Rectum. 2014;57:348&#x2013;353.</Citation></Reference><Reference><Citation>Qarabaki MA, Mukhashavria GA, Mukhashavria GG, Giorgadze NG. Circular vs. three-quadrant hemorrhoidectomy for end-stage hemorrhoids: short- and long-term outcomes of a prospective randomized trial. J Gastrointest Surg. 2014;18:808&#x2013;815.</Citation></Reference><Reference><Citation>J&#xf3;hannsson HO, Graf W, P&#xe5;hlman L. Long-term results of haemorrhoidectomy. Eur J Surg. 2002;168:485&#x2013;489.</Citation></Reference><Reference><Citation>Li YD, Xu JH, Lin JJ, Zhu WF. Excisional hemorrhoidal surgery and its effect on anal continence. World J Gastroenterol. 2012;18:4059&#x2013;4063.</Citation></Reference><Reference><Citation>Ross NP, Hildebrand DR, Tiernan JP, Brown SR, Watson AJ. Haemorrhoids: 21st-century management. Colorectal Dis. 2012;14:917&#x2013;919.</Citation></Reference><Reference><Citation>Trenti L, Biondo S, Galvez A, Bravo A, Cabrera J, Kreisler E. Distal Doppler-guided transanal hemorrhoidal dearterialization with mucopexy versus conventional hemorrhoidectomy for grade III and IV hemorrhoids: postoperative morbidity and long-term outcomes. Tech Coloproctol. 2017;21:337&#x2013;344.</Citation></Reference><Reference><Citation>Trenti L, Biondo S, Kreisler Moreno E, et al.; THDLIGA-RCT Study Group. Short-term outcomes of transanal hemorrhoidal dearterialization with mucopexy versus vessel-sealing device hemorrhoidectomy for grade III to IV hemorrhoids: a prospective randomized multicenter trial. Dis Colon Rectum. 2019;62:988&#x2013;996.</Citation></Reference><Reference><Citation>Denoya P, Tam J, Bergamaschi R. Hemorrhoidal dearterialization with mucopexy versus hemorrhoidectomy: 3-year follow-up assessment of a randomized controlled trial. Tech Coloproctol. 2014;18:1081&#x2013;1085.</Citation></Reference><Reference><Citation>Xu L, Chen H, Lin G, Ge Q, Qi H, He X. Transanal hemorrhoidal dearterialization with mucopexy versus open hemorrhoidectomy in the treatment of hemorrhoids: a meta-analysis of randomized control trials. Tech Coloproctol. 2016;20:825&#x2013;833.</Citation></Reference><Reference><Citation>Popov V, Yonkov A, Arabadzhieva E, et al. Doppler-guided transanal hemorrhoidal dearterilization versus conventional hemorrhoidectomy for treatment of hemorrhoids&#x2014;early and long-term postoperative results. BMC Surg. 2019;19:4.</Citation></Reference><Reference><Citation>Consalvo V, D&#x2019;Auria F, Salsano V. Transanal hemorrhoidal dearterialization with doppler arterial identification versus classic hemorrhoidectomy: a retrospective analysis of 270 patients. Ann Coloproctol. 2019;35:118&#x2013;122.</Citation></Reference><Reference><Citation>Giordano P, Nastro P, Davies A, Gravante G. Prospective evaluation of stapled haemorrhoidopexy versus transanal haemorrhoidal dearterialisation for stage II and III haemorrhoids: three-year outcomes. Tech Coloproctol. 2011;15:67&#x2013;73.</Citation></Reference><Reference><Citation>Vaizey CJ, Carapeti E, Cahill JA, Kamm MA. Prospective comparison of faecal incontinence grading systems. Gut. 1999;44:77&#x2013;80.</Citation></Reference><Reference><Citation>Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 health survey in nine countries: results from the IQOLA Project. International quality of life assessment. J Clin Epidemiol. 1998;51:1171&#x2013;1178.</Citation></Reference><Reference><Citation>Vilagut G, Valderas JM, Ferrer M, Garin O, L&#xf3;pez-Garc&#xed;a E, Alonso J. Interpretation of SF-36 and SF-12 questionnaires in Spain: physical and mental components [in Spanish]. Med Clin (Barc). 2008;130:726&#x2013;735.</Citation></Reference><Reference><Citation>Ratto C. THD Doppler procedure for hemorrhoids: the surgical technique. Tech Coloproctol. 2014;18:291&#x2013;298.</Citation></Reference><Reference><Citation>Du T, Quan S, Dong T, Meng Q. Comparison of surgical procedures implemented in recent years for patients with grade III and IV hemorrhoids: a network meta-analysis. Int J Colorectal Dis. 2019;34:1001&#x2013;1012.</Citation></Reference><Reference><Citation>R&#xf8;rvik HD, Campos AH, Styr K, et al. Minimal open hemorrhoidectomy versus transanal hemorrhoidal dearterialization: the effect on symptoms: an open-label randomized controlled trial. Dis Colon Rectum. 2020;63:655&#x2013;667.</Citation></Reference><Reference><Citation>Johannsson H&#xd6;, P&#xe5;hlman L, Graf W. Functional and structural abnormalities after Milligan hemorrhoidectomy: a comparison with healthy subjects. Dis Colon Rectum. 2013;56:903&#x2013;908.</Citation></Reference><Reference><Citation>Parello A, Litta F, De Simone V, et al. Haemorrhoidal haemodynamic changes in patients with haemorrhoids treated using Doppler-guided dearterialization. BJS Open. 2021;5:zrab012.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34890373</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem Cell Treatment) in Patients With Perianal Fistulizing Crohn's Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>720</EndPage><MedlinePgn>713-720</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002325</ELocationID><Abstract><AbstractText Label="BACKGROUND">Darvadstrocel is an expanded allogeneic adipose-derived mesenchymal stem cell therapy for the treatment of complex perianal fistulas in patients with Crohn's disease. Safety and efficacy outcomes from the clinical trial known as "Adipose derived mesenchymal stem cells for induction of remission in perianal fistulizing Crohn's disease," or ADMIRE-CD (NCT01541579), from up to 52 weeks posttreatment were previously reported. Here, the outcomes from an extended 104-week follow-up are reported.</AbstractText><AbstractText Label="OBJECTIVE">The goal of this study was to assess the long-term safety and efficacy of darvadstrocel at 2 years post-treatment in patients with Crohn's disease and complex perianal fistulas.</AbstractText><AbstractText Label="DESIGN">This was a phase 3 double-blind randomized controlled study (ADMIRE-CD) in patients with perianal fistulizing Crohn's disease.</AbstractText><AbstractText Label="SETTINGS">This study extension was conducted in multiple hospitals across 7 European countries and Israel.</AbstractText><AbstractText Label="PATIENTS">Forty patients entered the extended follow-up period: 25 patients in the darvadstrocel treatment group and 15 in the control group.</AbstractText><AbstractText Label="INTERVENTIONS">Darvadstrocel or saline solution (control group) was administered once, locally, after fistula tract curettage and internal opening closure (with previous seton placement). All patients were permitted to continue ongoing medical treatments for fistulas.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Treatment-emergent serious adverse events were recorded through week 104. Clinical remission, defined as closure of all treated external openings that were draining at baseline despite gentle finger compression, was assessed at week 104.</AbstractText><AbstractText Label="RESULTS">Of 40 patients, 37 completed the extended follow-up. Through week 104, 7 treatment-emergent serious adverse events were reported, of which 4 occurred between weeks 52 and 104. At week 104, clinical remission was reported in 14/25 (56%) patients in the darvadstrocel group and 6/15 (40%) patients in the control group.</AbstractText><AbstractText Label="LIMITATIONS">Limitations include the small number of patients who entered the extended follow-up period, and no imaging examinations were performed at the 104-week time point.</AbstractText><AbstractText Label="CONCLUSIONS">Darvadstrocel was well tolerated and clinical remission after treatment with darvadstrocel may be sustained for up to 104 weeks in patients with perianal fistulizing Crohn's disease. See Video Abstract at http://links.lww.com/DCR/B812.ClinicalTrials.gov No: NCT01541579.</AbstractText><AbstractText Label="ESTUDIO DE SEGUIMIENTO PARA EVALUAR LA SEGURIDAD Y EFICACIA A LARGO PLAZO DE DARVADSTROCEL TRATAMIENTO CON CLULAS MADRE MESENQUIMALES EN PACIENTES CON ENFERMEDAD DE CROHN PERIANAL FISTULIZANTE ENSAYO CONTROLADO ALEATORIZADO DE FASE ADMIRECD">ANTECEDENTES:Darvadstrocel es una terapia con c&#xe9;lulas madre mesenquimales alog&#xe9;nicas expandidas derivadas de tejido adiposo para el tratamiento de f&#xed;stulas perianales complejas en pacientes con enfermedad de Crohn. Los resultados del ensayo cl&#xed;nico conocido como "C&#xe9;lulas madre mesenquimales derivadas de tejido adiposo para la inducci&#xf3;n de la remisi&#xf3;n en la enfermedad de Crohn fistulizante perianal" o ADMIRE-CD (NCT01541579), en cuanto a la seguridad y eficacia hasta 52 semanas despu&#xe9;s del tratamiento, fueron previamente informados. Seguidamente, se presentan los resultados de un seguimiento extendido de 104 semanas.OBJETIVO:Evaluar la seguridad y eficacia a largo plazo de darvadstrocel a dos a&#xf1;os del tratamiento en pacientes con enfermedad de Crohn y f&#xed;stulas perianales complejas.DISE&#xd1;O:Este fue un estudio de fase 3, aleatorizado, a doble ciego, controlado (ADMIRE-CD) en pacientes con enfermedad de Crohn perianal fistulizante.DESARROLLO:Esta extensi&#xf3;n del estudio se realiz&#xf3; en varios hospitales de siete pa&#xed;ses europeos e Israel.PACIENTES:Cuarenta pacientes participaron en la extensi&#xf3;n de seguimiento: tratamiento con darvadstrocel (n = 25); grupo control (n = 15).INTERVENCIONES:Se administr&#xf3; Darvadstrocel o soluci&#xf3;n salina (grupo control) una vez, localmente, tras el legrado del trayecto f&#xed;stuloso y cierre del orificio interno (con la colocaci&#xf3;n previa de set&#xf3;n). A todos los pacientes se les permiti&#xf3; continuar con los tratamientos m&#xe9;dicos en curso para las f&#xed;stulas.PRINCIPALES MEDIDAS DE RESULTADO:Los eventos de efectos adversos graves derivados del tratamiento se registraron hasta la semana 104. La remisi&#xf3;n cl&#xed;nica, definida como el cierre de todas las aberturas externas tratadas que drenaban al inicio espont&#xe1;neamente o por compresi&#xf3;n suave de los dedos, fue evaluado en la semana 104.RESULTADOS:Del total de 40 pacientes, 37 completaron la extensi&#xf3;n de seguimiento. Hasta la semana 104, se reportaron 7 eventos de efectos adversos graves resultantes del tratamiento, de los cuales 4 ocurrieron entre las semanas 52 y 104. En la semana 104, se report&#xf3; remisi&#xf3;n cl&#xed;nica en 14/25 (56%) pacientes en el grupo de darvadstrocel y 6/15 (40%) pacientes en el grupo de control.LIMITACIONES:Solo una peque&#xf1;a cantidad de pacientes participaron en el per&#xed;odo de seguimiento extendido y no se realizaron ex&#xe1;menes por t&#xe9;cnicas de imagen en la visita a 104 semanas.CONCLUSIONES:Darvadstrocel fue bien tolerado y la remisi&#xf3;n cl&#xed;nica despu&#xe9;s del tratamiento con darvadstrocel puede mantenerse hasta 104 semanas en pacientes con enfermedad de Crohn perianal fistulizante. Consulte Video Resumen en http://links.lww.com/DCR/B812. (Traducci&#xf3;n-Dr Osvaldo Gauto and Dr Julian Pan&#xe9;s.)ClinicalTrials.gov No. NCT01541579.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garcia-Olmo</LastName><ForeName>Dami&#xe1;n</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universidad Aut&#xf3;noma de Madrid, Fundaci&#xf3;n Jim&#xe9;nez D&#xed;az, University Hospital, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilaberte</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals S.L., Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Binek</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D Hoore</LastName><ForeName>Andr&#xe9; J L</ForeName><Initials>AJL</Initials><AffiliationInfo><Affiliation>Universitair Ziekenhuis Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindner</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals International AG, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvaggi</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Colon and Rectal Surgery Unit, Department of Advanced Medical and Surgery Sciences, Luigi Vanvitelli University, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital, Division of Colon and Rectal Surgery, Rozzano Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan&#xe9;s</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Disease Unit, Hospital Cl&#xed;nic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01541579</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="Y">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>10</Day><Hour>17</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34890373</ArticleId><ArticleId IdType="pmc">PMC8985696</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002325</ArticleId><ArticleId IdType="pii">00003453-202205000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baumgart DC, Sandborn WJ. Crohn&#x2019;s disease. Lancet. 2012;380:1590&#x2013;1605.</Citation><ArticleIdList><ArticleId IdType="pubmed">22914295</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn&#x2019;s disease. Gastroenterology. 2003;125:1508&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pubmed">14598268</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaparro M, Burgueno P, Vera I, et al. . Epidemiological study of perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2011;140:S736.</Citation></Reference><Reference><Citation>Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn&#x2019;s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum. 2007;50:2067&#x2013;2074.</Citation><ArticleIdList><ArticleId IdType="pubmed">17680311</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A, Rodriguez-de-Santiago E, Lopez-Sanroman A. Management of complex perianal Crohn&#x2019;s disease. Ann Gastroenterol.2017;30:33&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5198245</ArticleId><ArticleId IdType="pubmed">28042236</ArticleId></ArticleIdList></Reference><Reference><Citation>Adegbola SO, Dibley L, Sahnan K, et al. . Burden of disease and adaptation to life in patients with Crohn&#x2019;s perianal fistula: a qualitative exploration. Health Qual Life Outcomes. 2020;18:370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7678264</ArticleId><ArticleId IdType="pubmed">33218361</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz DA, Loftus EV, Jr, Tremaine WJ, et al. . The natural history of fistulizing Crohn&#x2019;s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910338</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz DA, Tagarro I, Carmen D&#xed;ez M, Sandborn WJ. Prevalence of fistulizing Crohn&#x2019;s disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25:1773&#x2013;1779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6799946</ArticleId><ArticleId IdType="pubmed">31216573</ArticleId></ArticleIdList></Reference><Reference><Citation>Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn&#x2019;s disease in a population-based cohort. Dis Colon Rectum. 2012;55:773&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">22706129</ArticleId></ArticleIdList></Reference><Reference><Citation>Panes J, Reinisch W, Rupniewska E, et al. . Burden and outcomes for complex perianal fistulas in Crohn&#x2019;s disease: Systematic review. World J Gastroenterol. 2018;24:4821&#x2013;4834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6235801</ArticleId><ArticleId IdType="pubmed">30479468</ArticleId></ArticleIdList></Reference><Reference><Citation>Present DH, Rutgeerts P, Targan S, et al. . Infliximab for the treatment of fistulas in patients with Crohn&#x2019;s disease. N Engl J Med. 1999;340:1398&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10228190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sands BE, Anderson FH, Bernstein CN, et al. . Infliximab maintenance therapy for fistulizing Crohn&#x2019;s disease. N Engl J Med. 2004;350:876&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985485</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres J, Bonovas S, Doherty G, et al. . ECCO Guidelines on Therapeutics in Crohn&#x2019;s Disease: Medical Treatment. J Crohns Colitis. 2020;14:4&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">31711158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gionchetti P, Dignass A, Danese S, et al. .; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn&#x2019;s Disease 2016: Part 2: Surgical Management and Special Situations. J Crohns Colitis. 2017;11:135&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">27660342</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis. 2004;10:91&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">15168807</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohns Colitis. 2013;7:e302&#x2013;e311.</Citation><ArticleIdList><ArticleId IdType="pubmed">23228710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gecse KB, Bemelman W, Kamm MA, et al. .; World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials; World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn&#x2019;s disease. Gut. 2014;63:1381&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">24951257</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Olmo D, Garc&#xed;a-Arranz M, Herreros D, Pascual I, Peiro C, Rodr&#xed;guez-Montes JA. A phase I clinical trial of the treatment of Crohn&#x2019;s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005;48:1416&#x2013;1423.</Citation><ArticleIdList><ArticleId IdType="pubmed">15933795</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Portilla F, Alba F, Garc&#xed;a-Olmo D, Herrer&#xed;as JM, Gonz&#xe1;lez FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn&#x2019;s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2013;28:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">23053677</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharl M, Rogler G. Pathophysiology of fistula formation in Crohn&#x2019;s disease. World J Gastrointest Pathophysiol. 2014;5:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4133520</ArticleId><ArticleId IdType="pubmed">25133023</ArticleId></ArticleIdList></Reference><Reference><Citation>DelaRosa O, Dalemans W, Lombardo E. Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol. 2012;23:978&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">22682584</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al. .; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn&#x2019;s disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016;388:1281&#x2013;1290.</Citation><ArticleIdList><ArticleId IdType="pubmed">27477896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan&#xe9;s J, Garc&#xed;a-Olmo D, Van Assche G, et al. .; ADMIRE CD Study Group Collaborators. Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn&#x2019;s disease. Gastroenterology. 2018;154:1334&#x2013;1342.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29277560</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamina M, Bonovas S, Raine T, et al. . ECCO Guidelines on Therapeutics in Crohn&#x2019;s Disease: Surgical Treatment. J Crohns Colitis. 2020;14:155&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">31742338</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabalzar-Wondberg D, Turina M, Biedermann L, Rogler G, Schreiner P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn&#x2019;s disease: a case series. Colorectal Dis. 2021;23:1444&#x2013;1450.</Citation><ArticleIdList><ArticleId IdType="pubmed">33595166</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez N, Ramamoorthy S, Sandborn WJ. Recent advances in the management of perianal fistulizing Crohn&#x2019;s disease: lessons for the clinic. Expert Rev Gastroenterol Hepatol. 2019;13:563&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6545251</ArticleId><ArticleId IdType="pubmed">31023087</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein GR, Feagan BG, Cohen RD, et al. . Infliximab for Crohn&#x2019;s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176880</ArticleId><ArticleId IdType="pubmed">29462395</ArticleId></ArticleIdList></Reference><Reference><Citation>Zmora O, Pan&#xe9;s J, Drohan C, et al. . P491 inspire: design and implementation aspects of a registry of complex perianal fistulas in crohn&#x2019;s disease patients treated with darvadstrocel. J Crohn&#x2019;s Colitis. 2019;13(suppl 1):S357&#x2013;S358.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34629430</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Comparison of Curettage Plus Platelet-Rich Plasma Gel and Curettage Plus Phenol Application in Treatment of Pilonidal Sinus Disease: A Randomized Trial.</ArticleTitle><Pagination><StartPage>735</StartPage><EndPage>741</EndPage><MedlinePgn>735-741</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002082</ELocationID><Abstract><AbstractText Label="BACKGROUND">As a chronic condition, pilonidal disease affects a young population, and recovery after the surgical procedures performed to treat this condition require time off from work. Therefore, the search for an ideal treatment is still ongoing.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to compare early and late results of 2 minimally invasive treatment options used to treat pilonidal disease.</AbstractText><AbstractText Label="DESIGN">This study was designed as a parallel group randomized clinical trial.</AbstractText><AbstractText Label="SETTINGS">This study took place at an outpatient clinic in Turkey.</AbstractText><AbstractText Label="PATIENTS">Patients with pilonidal disease were evaluated for the study and were enrolled if they met the inclusion criteria and gave informed consent.</AbstractText><AbstractText Label="INTERVENTIONS">Patients in the platelet-rich plasma group were treated using curettage + platelet-rich plasma gel. Patients in the phenol group were treated by using curettage + crystallized phenol.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary study end point was the time to achieve healing; the secondary outcome was recurrence rate.</AbstractText><AbstractText Label="RESULTS">In the platelet-rich plasma group, 96% of patients achieved healing after 1 application. In the phenol group, only 53% patients achieved healing after 1 application. The median healing time was shorter in the platelet-rich plasma group: 6 (4-14) vs 10 (5-42) days (p &lt; 0.001). The mean difference in healing was 5.8 days (95% CI, 4.27-7.38). After a mean follow-up of 43.1 months, there was a 4% recurrence rate in the platelet-rich plasma group in comparison with a 12% recurrence rate in the phenol group (95% CI, 0.024-0.251).</AbstractText><AbstractText Label="LIMITATIONS">Despite the randomized prospective nature of the study, neither the patients nor the investigators were blinded.</AbstractText><AbstractText Label="CONCLUSIONS">The curettage + platelet-rich plasma method can be safely applied with an improved healing time, low recurrence rate, and minimal time off work. See Video Abstract at http://links.lww.com/DCR/B722.Clinical Trial Registration: NCT03070028.</AbstractText><AbstractText Label="COMPARACIN DE CURETAJE MS GEL DE PLASMA RICO EN PLAQUETAS Y LA APLICACIN DE CURETAJE MS FENOL EN EL TRATAMIENTO DE LA ENFERMEDAD DEL SENO PILONIDAL ENSAYO ALEATORIZADO">ANTECEDENTES:Como condici&#xf3;n cr&#xf3;nica, la enfermedad pilonidal afecta a una poblaci&#xf3;n joven y los procedimientos quir&#xfa;rgicos que se realizan para tratar esta condici&#xf3;n requieren un tiempo de recuperaci&#xf3;n con baja laboral. Por lo tanto, la b&#xfa;squeda del tratamiento ideal a&#xfa;n est&#xe1; en curso.OBJETIVO:El objetivo de este estudio es comparar los resultados tempranos y tard&#xed;os de dos opciones de tratamiento m&#xed;nimamente invasivos utilizados para tratar la enfermedad pilonidal.DISE&#xd1;O:Este estudio est&#xe1; dise&#xf1;ado como un ensayo cl&#xed;nico aleatorizado de dos grupos paralelos.ENTORNO CL&#xcd;NICO:El estudio consta de dos grupos: curetaje + plasma rico en plaquetas y curetaje + fenol.PACIENTES:Los pacientes con enfermedad pilonidal fueron evaluados para el estudio y se inscribieron si cumpl&#xed;an con los criterios de inclusi&#xf3;n y dieron su consentimiento informado.INTERVENCIONES:Los pacientes del grupo de plasma rico en plaquetas fueron tratados con curetaje + gel de plasma rico en plaquetas. En el grupo de fenol, los pacientes fueron tratados con curetaje + fenol cristalizado.PRINCIPALES MEDIDAS DE RESULTADO: El principal criterio de valoraci&#xf3;n del estudio fue el tiempo para lograr la curaci&#xf3;n; el resultado secundario fue la tasa de recurrencia.RESULTADOS:En el grupo de plasma rico en plaquetas, el 96% de los casos logr&#xf3; la curaci&#xf3;n despu&#xe9;s de una aplicaci&#xf3;n. En el grupo de fenol, solo el 53% de los casos lograron la curaci&#xf3;n despu&#xe9;s de una aplicaci&#xf3;n. La mediana del tiempo de curaci&#xf3;n fue m&#xe1;s corta en el grupo de plasma rico en plaquetas; 6 (4-14) vs 10 (5-42) d&#xed;as (p &lt; 0,001). La diferencia media en la curaci&#xf3;n fue de 5,8 d&#xed;as (IC del 95%: 4,27-7,38). Despu&#xe9;s de un seguimiento medio de 43,1 meses, hubo una tasa de recurrencia del 4% en el grupo de plasma rico en plaquetas en comparaci&#xf3;n con una tasa de recurrencia del 12% en el grupo de fenol (IC del 95%: 0.024-0.251).LIMITACIONES:A pesar de la naturaleza prospectiva aleatorizada del estudio, ni los pacientes ni los investigadores fueron cegados.CONCLUSIONES:El m&#xe9;todo de legrado + plasma rico en plaquetas se puede aplicar de forma segura con un mejor tiempo de curaci&#xf3;n, una tasa de recurrencia baja y un tiempo de baja laboral m&#xed;nimo. Consulte Video Resumen en http://links.lww.com/DCR/B722 (Traducci&#xf3;n-Dr. Yazmin Berrones-Medina).Este ensayo se registr&#xf3; para ensayos cl&#xed;nicos con ID: NCT03070028. El protocolo completo se puede encontrar en https://clinicaltrials.gov/ct2/show/NCT03070028.</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sevin&#xe7;</LastName><ForeName>Bari&#x15f;</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Surgery, U&#x15f;ak University School of Medicine, U&#x15f;ak, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damburaci</LastName><ForeName>Nurullah</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Karahan</LastName><ForeName>&#xd6;mer</ForeName><Initials>&#xd6;</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03070028</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>339NCG44TV</RegistryNumber><NameOfSubstance UI="D019800">Phenol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2022 Apr 1;65(4):e248. doi: 10.1097/DCR.0000000000002404.</RefSource><PMID Version="1">34984999</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2022 Apr 1;65(4):e249. doi: 10.1097/DCR.0000000000002405.</RefSource><PMID Version="1">34985001</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003475" MajorTopicYN="N">Curettage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019800" MajorTopicYN="N">Phenol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010864" MajorTopicYN="Y">Pilonidal Sinus</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053657" MajorTopicYN="Y">Platelet-Rich Plasma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34629430</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002082</ArticleId><ArticleId IdType="pii">00003453-202205000-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duman K, Girgin M, Harlak A. Prevalence of sacrococcygeal pilonidal disease in Turkey. Asian J Surg. 2017;40:434&#x2013;437.</Citation></Reference><Reference><Citation>Altintoprak F, Dikicier E, Arslan Y, Ozkececi T, Akbulut G, Dilek ON. Comparison of the Limberg flap with the V-Y flap technique in the treatment of pilonidal disease. J Korean Surg Soc. 2013;85:63&#x2013;67.</Citation></Reference><Reference><Citation>Topuz O, S&#xf6;zen S, T&#xfc;kenmez M, Topuz S, Vurdem UE. Crystallized phenol treatment of pilonidal disease improves quality of life. Indian J Surg. 2014;76:81&#x2013;84.</Citation></Reference><Reference><Citation>Sevin&#xe7; B, Damburaci N, Karahan &#xd6;. Long term results of minimally invasive treatment of pilonidal disease by platelet rich plasma. J Visc Surg. 2020;157:33&#x2013;35.</Citation></Reference><Reference><Citation>Girgin M, Kanat BH. The results of a one-time crystallized phenol application for pilonidal sinus disease. Indian J Surg. 2014;76:17&#x2013;20.</Citation></Reference><Reference><Citation>Karahan &#xd6;, Sevin&#xe7; B, &#x15e;im&#x15f;ek G, Demirg&#xfc;l R. Minimally invasive treatment of pilonidal sinus disease using platelet-rich plasma. Transl Surg. 2016;1:14&#x2013;17.</Citation></Reference><Reference><Citation>Maurice BA, Greenwood RK. A conservative treatment of pilonidal sinus. Br J Surg. 1964;51:510&#x2013;512.</Citation></Reference><Reference><Citation>Dogru O, Camci C, Aygen E, Girgin M, Topuz O. Pilonidal sinus treated with crystallized phenol: an eight-year experience. Dis Colon Rectum. 2004;47:1934&#x2013;1938.</Citation></Reference><Reference><Citation>Sak&#xe7;ak I, Av&#x15f;ar FM, Co&#x15f;gun E. Comparison of the application of low concentration and 80% phenol solution in pilonidal sinus disease. JRSM Short Rep. 2010;1:5.</Citation></Reference><Reference><Citation>Chicharro-Alc&#xe1;ntara D, Rubio-Zaragoza M, Dami&#xe1;-Gim&#xe9;nez E, et al. Platelet rich plasma: new insights for cutaneous wound healing management. J Funct Biomater. 2018;9:E10.</Citation></Reference><Reference><Citation>Villela DL, Santos VL. Evidence on the use of platelet-rich plasma for diabetic ulcer: a systematic review. Growth Factors. 2010;28:111&#x2013;116.</Citation></Reference><Reference><Citation>Pallua N, Wolter T, Markowicz M. Platelet-rich plasma in burns. Burns. 2010;36:4&#x2013;8.</Citation></Reference><Reference><Citation>Carter MJ, Fylling CP, Parnell LK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty. 2011;11:e38.</Citation></Reference><Reference><Citation>Gips M, Melki Y, Salem L, Weil R, Sulkes J. Minimal surgery for pilonidal disease using trephines: description of a new technique and long-term outcomes in 1,358 patients. Dis Colon Rectum. 2008;51:1656&#x2013;1662.</Citation></Reference><Reference><Citation>Stansby G, Greatorex R. Phenol treatment of pilonidal sinuses of the natal cleft. Br J Surg. 1989;76:729&#x2013;730.</Citation></Reference><Reference><Citation>Girgin M, Kanat BH, Ayten R, et al. Minimally invasive treatment of pilonidal disease: crystallized phenol and laser depilation. Int Surg. 2012;97:288&#x2013;292.</Citation></Reference><Reference><Citation>Akan K, Tihan D, Duman U, &#xd6;zg&#xfc;n Y, Erol F, Polat M. Comparison of surgical Limberg flap technique and crystallized phenol application in the treatment of pilonidal sinus disease: a retrospective study. Ulus Cerrahi Derg. 2013;29:162&#x2013;166.</Citation></Reference><Reference><Citation>K&#xe4;ser SA, Zengaffinen R, Uhlmann M, Glaser C, Maurer CA. Primary wound closure with a Limberg flap vs. secondary wound healing after excision of a pilonidal sinus: a multicentre randomised controlled study. Int J Colorectal Dis. 2015;30:97&#x2013;103.</Citation></Reference><Reference><Citation>Mohammadi S, Nasiri S, Mohammadi MH, et al. Evaluation of platelet-rich plasma gel potential in acceleration of wound healing duration in patients underwent pilonidal sinus surgery: a randomized controlled parallel clinical trial. Transfus Apher Sci. 2017;56:226&#x2013;232.</Citation></Reference><Reference><Citation>Mohamadi S, Norooznezhad AH, Mostafaei S, et al. A randomized controlled trial of effectiveness of platelet-rich plasma gel and regular dressing on wound healing time in pilonidal sinus surgery: role of different affecting factors. Biomed J. 2019;42:403&#x2013;410.</Citation></Reference><Reference><Citation>Mostafaei S, Norooznezhad F, Mohammadi S, Norooznezhad AH. Effectiveness of platelet-rich plasma therapy in wound healing of pilonidal sinus surgery: a comprehensive systematic review and meta-analysis. Wound Repair Regen. 2017;25:1002&#x2013;1007.</Citation></Reference><Reference><Citation>Alamdari DH, Motie MR, Kamalahmadi N, Aliakbarian M. Autologous platelet-rich plasma and fibrin glue decrease pain following excision and primary closure of pilonidal sinus. Adv Skin Wound Care. 2019;32:234&#x2013;237.</Citation></Reference><Reference><Citation>Calikoglu I, Gulpinar K, Oztuna D, et al. Phenol injection versus excision with open healing in pilonidal disease: a prospective randomized trial. Dis Colon Rectum. 2017;60:161&#x2013;169.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>